What happens if we start using induced pluripotent stem (iPS) cells clinically in humans? A cool new paper recently came out that gets us closer to being able to predict an answer. It’s an important question as iPS cell-derived cellular products are getting closer to clinical use. For example, the first iPS cell-based clinical trial began to enroll patients in Japan last year in a clinical study related to macular degeneration (see my interview with Dr. Masayo Takahashi, who is leading that intriguing study). …Read More
Knoepfler lab stem cell blog
